3750 – Anti-GP2 IgA

Highlights

• Use of recombinant human glycoprotein 2 (GP2)
• Ready-to-use (exception: conjugate and wash buffer) and barcoded reagents
• Quality assured handling in routine laboratories
• Incubation at room temperature
• Quantitative determination of IgA antibodies against GP2
• Calibrated with the international standard preparation NIBSC code 08/204
• Results expressed in IU/L
• Excellent diagnostic sensitivity and specificity
• High precision within the measurement range
• CE marked
• Automatable

Intended Purpose

The Anti-GP2 IgA is a quantitative immunoassay for the determination of IgA antibodies against glycoprotein 2 (GP2) in human serum. The Anti-GP2 IgA is intended as an aid in the diagnosis of Crohn’s disease in conjunction with other clinical and laboratory findings. The immunoassay is designed for manual professional in vitro diagnostic use.

Diagnostic Relevance

Non-specific inflammatory bowel diseases, including Crohn’s disease (CD, enteritis regionalis) and ulcerative colitis (UC), involve chronic relapsing inflammatory processes of the intestine. Immunologic, genetic, infectious, and environmental factors contribute to the risk of developing these diseases. Researchers identified autoantibodies of the exocrine pancreas (PAB) as specific serological markers for CD. Membrane-bound pancreatic glycoprotein 2 (GP2) represents the major target of PAB. In combination with the detection of autoantibodies to Saccharomyces cerevisiae (ASCA), which occur in approximately 70% of CD patients, and atypical antineutrophil cytoplasmic antibodies (aANCA), mainly detected in UC patients, PAB against GP2 serve as highly specific serological markers for differentiating CD from UC.

Publications

• Rausch et al., (2025) First insights into microbial changes within an Inflammatory Bowel Disease Family Cohort study
• Shpoliansky et al., (2021) Antibodies Against Glycoprotein 2 Are Specific Biomarkers for Pediatric Crohn's Disease
• Duman et al., (2019) Differential diagnosis of Crohn's disease using antibodies to glycoprotein 2 and Saccharomyces cerevisiae
• Tornai et al., (2018) Loss of tolerance to gut immunity protein, glycoprotein 2 (GP2) is associated with progressive disease course in primary sclerosing cholangitis
• Zhang et al., (2018) Antibodies against glycoprotein 2 display diagnostic advantages over ASCA in distinguishing CD from intestinal tuberculosis and intestinal Behçet's disease
• Bogdanos et al., (2012) Pancreatic-specific autoantibodies to glycoprotein 2 mirror disease location and behaviour in younger patients with Crohn's disease